Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD). No liver injury has been observed with tolvaptan treatment in healthy subjects and in non-ADPKD indications, but ADPK...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Toxicol Sci
Main Authors: Woodhead, Jeffrey L., Brock, William J., Roth, Sharin E., Shoaf, Susan E., Brouwer, Kim L.R., Church, Rachel, Grammatopoulos, Tom N., Stiles, Linsey, Siler, Scott Q., Howell, Brett A., Mosedale, Merrie, Watkins, Paul B., Shoda, Lisl K.M.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Mechanisms of Tolvaptan-Induced Liver Injury
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5216653/
https://ncbi.nlm.nih.gov/pubmed/27655350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/toxsci/kfw193
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados